Chemotherapy-Induced Peripheral Neuropathy (CIPN)
Chemotherapy is widely used for the treatment of various cancers. However, chemotherapeutic agents cause debilitating peripheral neuropathy, which results in discontinuation of the treatment or alteration of the treatment schedule. Chemotherapy-induced peripheral neuropathy (CIPN) is characterized by severe pain and numbness with the symptoms lasting long after the onset. Lack of understanding of the mechanisms underling CIPN hampers the efforts to develop the treatments.
The half life of chemotherapies is short in vivo, thus it is believed that chemotherapies cause CIPN via a transient action and is widely accepted that it is necessary to develop regulatable gene expression vectors for the treatment. Our current work is focused on dissecting the mechanism by which paclitaxel induces CIPN and to develop and test -herpes simplex virus (HSV)-based regulatable GP-P and neurotrophin expression vectors for the treatment.